Company intelligence / Profile preview

Kuhnkarb

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Kuhnkarb is a biotechnology company focused on developing next-generation small molecule therapeutics for oncology. The company's lead research program targets Hypoxia-inducible factor 2-alpha (HIF-2α), a key driver in the progression of clear cell renal cell carcinoma and other solid tumors. Kuhnkarb aims to improve upon existing HIF-2α inhibitors by developing molecules with enhanced potency and better pharmacological profiles. The company is currently in the pre-clinical stage of development, advancing its lead candidates toward IND-enabling studies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Kuhnkarb.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kuhnkarb.

Explore the full profile